Associated Papers
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
Mutations in Classical Signaling Pathways and Their Functional Impact in Microsatellite Instability High Colorectal Cancer.
Shi S et al.
Genetic Testing and Molecular Biomarkers, 2023
Delineating the RAS Conformational Landscape.
Parker MI et al.
Cancer Research, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis.
Hoefflin R et al.
Cancers, 2021
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
Kemps PG et al.
The Journal of Pathology. Clinical Research, 2021
Ras Variant Biology and Contributions to Human Disease.
Prior I
Methods in Molecular Biology (clifton, N.j.), 2021
Development of Noonan syndrome by deregulation of allosteric SOS autoactivation.
Umutesi HG et al.
The Journal of Biological Chemistry, 2020
Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
Diefenbach RJ et al.
Cancers, 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis.
Takahara S et al.
Ebiomedicine, 2019
Noonan syndrome: lessons learned from genetically modified mouse models.
Schuhmacher AJ et al.
Expert Review of Endocrinology & Metabolism, 2017
Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies.
Bueno A et al.
Oncotarget, 2016
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
Madan V et al.
Leukemia, 2016
Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology.
Jesinghaus M et al.
Genes, Chromosomes & Cancer, 2016
The impact of the genetic background in the Noonan syndrome phenotype induced by K-Ras(V14I).
Hernández-Porras I et al.
Rare Diseases (austin, Tex.), 2015
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
Amato E et al.
The Journal of Pathology, 2014
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C et al.
Molecular Systems Biology, 2014
Characterization of a novel KRAS mutation identified in Noonan syndrome.
Razzaque MA et al.
American Journal of Medical Genetics. Part A, 2012
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
Vaughn CP et al.
Genes, Chromosomes & Cancer, 2011
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
Rauen KA et al.
American Journal of Medical Genetics. Part A, 2010
Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.
Lo FS et al.
European Journal of Pediatrics, 2009
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Tyner JW et al.
Blood, 2009
Germline KRAS mutations cause Noonan syndrome.
Schubbert S et al.
Nature Genetics, 2006